COVID-19 is best known for respiratory symptoms like cough and congestion, but it can also affect your skin.
A COVID rash is a skin manifestation that some people develop before, during, or shortly after infection, appearing in various forms from hives and red spots to blistering and the distinctive “COVID toes.”
While not as common as fever or fatigue, these skin changes affect a notable portion of patients and can be one of the first signs of infection.
The appearance varies widely between individuals, making identification tricky.
Some people notice itchy patches on their torso, while others develop painful discoloration on their toes.
What Is a Covid Rash?
A Covid rash refers to skin changes that can occur during or after infection with SARS-CoV-2, the virus causing COVID-19.
These rashes vary widely in appearance and affect roughly 20% of people with the disease.
Covid Rash vs. Other Viral Rashes
Covid rashes can mimic other viral skin reactions.
A typical viral rash from COVID-19 presents as itchy, red patches on fair skin or purple-brown discoloration on darker skin tones.
What sets Covid rashes apart is their unpredictability.
Unlike chickenpox, which follows a consistent pattern, COVID-19 rash appearances range from hives to small fluid-filled blisters to the distinctive “COVID toes” with pink or red sores.
The inflammation driving these skin changes stems from how the immune system responds to SARS-CoV-2.
Covid-19 rashes can appear on toes, fingers, trunk, and limbs without following predictable distribution patterns.
How Common Are Covid Rashes?
Covid rashes affect approximately 20% of patients with COVID-19.
For some, skin symptoms represent the only clinical sign of infection.
Rashes aren’t limited to severe cases.
They appear across all types of COVID-19 presentations, from asymptomatic to critical.
Skin manifestations can appear at any stage—during active infection, as an early warning sign, or as part of long COVID syndrome.
Despite their prevalence, Covid rashes remain less recognized than respiratory symptoms.
This creates challenges for diagnosis when skin changes appear without fever or cough.
Covid Rash in Adults and Children
Both adults and children develop Covid rashes, though most research centers on adult cases.
The presentation doesn’t differ dramatically between age groups, but children may show slightly different patterns.
In adults, we commonly observe hives-like welts, maculopapular eruptions resembling measles, and chilblain-like lesions (“COVID toes”).
In children, the same types appear but often with viral exanthem patterns, less severe inflammation, and faster resolution.
The itchiness varies between individuals regardless of age.
Some experience intense scratching, while others report minimal discomfort.
Duration also spans a wide range, from days to weeks after infection clears.
Types of Covid Rash
COVID-19 produces several distinct skin patterns that help doctors identify potential cases.
These rashes range from widespread bumpy eruptions to localized discoloration on fingers and toes.
Morbilliform Rash
Morbilliform rash appears as small, flat or slightly raised red bumps spread across the body.
This pattern resembles measles and is the most frequently reported skin manifestation in COVID-19 patients.
The rash typically develops on the trunk first, then spreads to the arms and legs.
It appears pink or red on lighter skin tones and purple-brown on darker complexions.
Most people notice this rash appearing around the same time as their respiratory symptoms, though some develop it a few days before or after.
The bumps don’t usually hurt, but many report mild itching.
Healthcare providers often struggle to distinguish this rash from drug reactions, since many COVID patients take multiple medications.
The rash generally resolves within eight days without special treatment.
Urticaria (Hives)
Urticaria presents as raised, itchy welts that can appear anywhere on the body.
These hives look like mosquito bites but tend to be larger and more widespread.
COVID-related hives may last longer than standard hives and can persist throughout the infection.
Some patients develop widespread hives while others experience localized patches.
The itching can range from mild to severe.
Urticaria sometimes appears as the first symptom of COVID-19, even before fever or cough.
Standard antihistamines usually provide relief, though the hives may return until the infection clears.
Vesicular Rash
Vesicular rash consists of small, fluid-filled blisters that resemble chickenpox.
This pattern occurs less frequently than morbilliform rash but is quite distinctive.
The blisters typically measure 2-4 millimeters across and contain clear or slightly cloudy fluid.
They most commonly appear on the trunk but can develop on the arms, legs, or face.
The rash itches intensely in most cases.
These vesicles tend to appear later in the disease course, often around 14 days after initial symptoms.
Some patients develop just a few scattered blisters while others experience widespread eruptions.
The blisters eventually crust over and heal within two weeks.
Covid Toes and Chilblain-Like Lesions
COVID toes manifest as red or purple discoloration on the toes or fingers, resembling chilblains from cold exposure.
This finding became one of the signature skin manifestations early in the pandemic.
The affected digits develop painful, swollen areas that may blister or peel.
Unlike true chilblains, COVID toes appear even in warm climates and during summer months.
These lesions affect children and young adults more frequently.
Patients often describe burning, itching, or tenderness in the affected areas.
The discoloration can last for weeks or even months.
People who develop COVID toes often have mild or no respiratory symptoms.
Other Covid-Associated Skin Manifestations
Beyond COVID toes, the virus triggers several other distinctive skin changes that range from mild rashes to serious vascular complications.
These manifestations include papular and maculopapular eruptions, pityriasis rosea-like presentations, and vascular patterns like livedo reticularis and purpura.
Papular and Maculopapular Rashes
Papular and maculopapular rashes are among the most frequently reported skin changes in COVID-19 patients.
These rashes appear as small, raised bumps (papules) or a combination of flat spots (macules) and raised areas.
They typically occur on the trunk and limbs but can appear anywhere on the body.
The lesions often resemble viral exanthems or morbilliform rashes.
Most patients describe itching as a primary symptom.
The rash appears red on lighter skin tones and purple-brown on darker complexions.
Key characteristics include duration of 7-9 days, primary locations on the trunk and limbs, and self-limiting nature with gradual resolution.
These rashes don’t typically require specific treatment beyond symptom management.
Their appearance often coincides with other COVID-19 symptoms.
Pityriasis Rosea
Some COVID-19 patients develop rashes that closely mimic pityriasis rosea, a common skin condition.
This creates diagnostic challenges for healthcare providers.
The rash pattern typically starts with a larger “herald patch” followed by smaller lesions spreading across the body.
These oval-shaped patches often arrange themselves along skin tension lines, creating a “Christmas tree” pattern on the back.
The lesions may be scaly around the edges with central clearing.
Cases have been documented where patients presented with this pattern alongside confirmed COVID-19 infection.
Treatment is largely supportive, with moisturizers and antihistamines helping manage any itching.
Livedo Reticularis and Purpura
Livedo reticularis and purpura are the most concerning COVID-associated skin manifestations because they signal underlying vascular complications.
Livedo reticularis appears as a mottled, net-like pattern of reddish-blue discoloration, indicating partial blood vessel occlusion.
Purpura manifests as purple or red spots that don’t blanch when pressed, caused by bleeding under the skin.
Retiform purpura—a specific subtype with a net-like or branching pattern—indicates complete vascular occlusion and is associated with severe disease in critically ill patients.
These vascular lesions correlate with elevated D-dimer levels, disseminated intravascular coagulation (DIC), and increased risk of thrombotic events.
They are recognized as medical emergencies requiring immediate intervention.
The hypercoagulable state in severe COVID-19 triggers excessive clotting that damages small blood vessels in the skin and internal organs.
Healthcare providers must monitor for these signs, as they often appear in hospitalized patients and demand aggressive anticoagulation therapy.
Symptoms and Appearance
Covid rashes manifest in multiple forms, from flat discolored patches to raised bumps, and can appear at different stages of infection.
The timing, location, and specific characteristics vary considerably between individuals and viral strains.
Common Features of Covid Rash
Covid rashes typically follow distinct patterns.
The most frequently reported types include maculopapular rashes (flat or slightly raised discolored areas), papulovesicular rashes (raised, fluid-filled blisters), and urticarial rashes (itchy, discolored patches resembling hives).
Covid toes are particularly recognizable, appearing as darkened, reddish, or purple areas on the toes and sometimes fingers.
The discoloration can resemble frostbite or chilblains.
Some rashes emerge early in infection, while others develop days or weeks after other symptoms.
In some cases, skin changes are the only indication of Covid-19 infection.
Rashes can appear on the chest, trunk, extremities, toes, and fingers.
Key characteristics include texture (flat patches, raised bumps, fluid-filled blisters), color (red, purple, pink, or darker pigmentation depending on skin tone), duration (days to several weeks), and sensation (itchy or asymptomatic).
Symptoms of Covid-19 with Rash
When rashes occur alongside respiratory symptoms, patients typically experience the standard Covid-19 symptoms first.
Fever frequently accompanies skin manifestations, particularly in the early infection stage.
Fatigue is also a common concurrent symptom.
Respiratory indicators often include shortness of breath, cough, and congestion.
Some individuals develop skin changes before experiencing any breathing difficulties or fever.
Maculopapular rashes tend to develop later in the infection course, while papulovesicular presentations often emerge at the infection’s onset.
Children may experience more severe inflammatory responses.
Multisystem inflammatory syndrome in children (MIS-C) is a serious condition where rashes accompany widespread inflammation affecting multiple organ systems.
Covid Rash in Darker Skin Tones
Diagnostic challenges are greater in patients with darker skin tones.
Natural skin pigmentation can camouflage inflammation and discoloration, leading to missed or delayed identification of Covid rashes.
Redness that appears obvious on lighter skin may show as subtle purple, brown, or darker patches on melanin-rich skin.
This effect particularly impacts the detection of maculopapular and papulovesicular rashes.
Healthcare providers must examine patients for texture changes, swelling, or warmth rather than relying solely on color.
Patients should monitor for raised areas, unusual bumps, or changes in skin texture.
Recognition gaps contribute to underreporting of skin manifestations in diverse populations.
Increased vigilance for any skin changes during or after Covid-19 exposure is recommended, regardless of how subtle they may seem.
Who Gets Covid Rash and When?
Covid rash can affect anyone who contracts the virus.
Most rashes appear within the first week of infection and resolve within days to weeks, but some persist for months in cases of long Covid.
Covid Rash Timing and Duration
Covid rashes can emerge at various points during infection. Some people develop skin symptoms before other signs of illness, while others notice rashes days after initial Covid symptoms begin.
The most common timing falls within the first few days to two weeks of infection. Most Covid-related skin changes last between 2 and 12 days, with an average duration of 8 days.
Certain rash types correlate with disease severity. Hives and Covid toes are more common in milder cases, while vaso-occlusive lesions—blocked blood vessels causing skin discoloration—are linked to more severe infections requiring intensive care.
Immunocompromised individuals may experience longer-lasting or more severe rashes due to altered immune responses. Some hospitalized patients also experience virus reactivation, triggering conditions like shingles or cold sores alongside Covid infection.
Rash in Long Covid
Long Covid affects roughly 10-30% of infected individuals, and skin manifestations can be part of this extended illness. Some rashes persist for months beyond the initial infection, defying the typical 2-12 day timeline.
These prolonged rashes may wax and wane, making them difficult to track. The mechanisms behind long Covid rashes remain under investigation, but ongoing inflammation and immune system dysregulation are suspected factors.
People with long Covid report persistent skin symptoms including recurring hives, discoloration patches, and continued sensitivity. These often appear alongside other long Covid symptoms like fatigue, brain fog, and breathing difficulties.
Causes and Risk Factors
COVID-19 rashes stem from the body’s immune response to SARS-CoV-2 infection. Some skin reactions also arise from medications used during treatment or flare-ups of pre-existing conditions.
How Covid-19 Triggers Skin Changes
SARS-CoV-2 enters human cells by binding to ACE2 receptors, found in the lungs and in blood vessels throughout the skin. This triggers an inflammatory cascade that can manifest as various skin conditions.
The immune response to COVID-19 involves several mechanisms:
- Direct viral damage to small blood vessels in the skin
- Inflammatory cytokines affecting skin cells
- Microclots in tiny capillaries, visible in conditions like COVID toes
- Immune complex deposition leading to vasculitis-type reactions
About 20% of COVID-19 patients develop some form of rash. The virus can cause morbilliform eruptions (measles-like spots), urticaria (hives), vesicular lesions (small blisters), and chilblain-like lesions on toes and fingers.
These reactions typically appear within the first week of infection, though COVID toes often emerge later.
Medication Reactions and Underlying Skin Conditions
Antiviral medications like remdesivir and nirmatrelvir can cause skin reactions that mimic COVID rash. Distinguishing between virus-induced rashes and drug hypersensitivity reactions is crucial.
Pre-existing skin conditions often worsen during COVID-19 infection due to immune system activation and stress. Eczema, psoriasis, and acne are particularly susceptible to flare-ups or worsening during active infection.
The inflammatory state triggered by SARS-CoV-2 exacerbates these underlying conditions. Drug reactions tend to occur within days of starting treatment, while viral rashes often precede or accompany respiratory symptoms.
Diagnosis and When to Seek Medical Help
COVID rashes are diagnosed through medical history and physical examination. Certain severe presentations require immediate medical attention.
When Rash Indicates Severe Covid-19
Some rashes signal severe disease. Vaso-occlusive lesions—such as livedo reticularis (lace-like discoloration), purpuric spots (purple patches that don’t blanch), and acral ischemia (tissue death in fingers or toes)—indicate potential blood clotting complications.
These patterns appear most frequently in hospitalized patients with moderate to severe infections. Immediate care is necessary if a rash appears alongside:
- Difficulty breathing or persistent chest pain
- Confusion or inability to stay awake
- Bluish lips or face
- Rapidly spreading purple or black discoloration on extremities
A skin biopsy may be needed when the diagnosis is uncertain or to rule out life-threatening conditions like Stevens-Johnson syndrome or toxic epidermal necrolysis.
Multisystem Inflammatory Syndrome (MIS)
Multisystem inflammatory syndrome is a rare but serious complication that can develop weeks after COVID-19 infection. It causes inflammation across multiple organ systems and often presents with persistent rashes.
MIS typically occurs 2-6 weeks post-infection and affects both children (MIS-C) and adults (MIS-A). The syndrome can impact the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.
Warning signs requiring emergency evaluation include:
- Persistent fever lasting several days
- Rash with red eyes, swollen lips, or “strawberry tongue”
- Severe abdominal pain, vomiting, or diarrhea
- Rapid heartbeat or chest discomfort
- Swollen hands or feet
Immediate medical attention is essential, as MIS requires hospitalization and intensive treatment.
Treatment and Management of Covid Rash
Most covid rashes resolve on their own within one to two weeks. Several treatment options can ease discomfort and speed recovery.
Home Care and Relief Options
Basic skincare measures are effective for mild covid rashes. Cool compresses applied for 10-15 minutes several times daily can reduce inflammation and soothe itching.
Over-the-counter options include:
- Moisturizing lotions—use fragrance-free creams to prevent dryness
- Calamine lotion—reduces itching and irritation
- Hydrocortisone cream (1%)—eases mild inflammation
Patients should avoid scratching to prevent secondary infections. Loose, breathable clothing reduces friction, and lukewarm baths with colloidal oatmeal can help with widespread rashes.
For covid toes, keeping feet warm and elevated is usually sufficient.
Medications and Hospital Treatments
If home remedies are insufficient, medical intervention may be necessary. Antihistamines like diphenhydramine or cetirizine control itching and reduce hives-like rashes.
Corticosteroids—topical for localized rashes, oral prednisone for severe or widespread cases—can suppress the immune response causing skin inflammation. In rare cases involving blood clotting issues, anticoagulants may be prescribed.
Some patients find rashes improve as the underlying infection clears with antiviral treatment. Treatment depends on rash type and severity; blistering rashes or those with fever require immediate medical evaluation.
Prevention Strategies
Preventing COVID-19 rash centers on avoiding infection through vaccination and proper protective equipment use. Vaccination remains the most effective tool.
Vaccination and Covid-19 Vaccine Reactions
COVID-19 vaccines from Moderna, Pfizer, and others significantly reduce infection risk and disease severity. Some individuals develop temporary skin reactions at the injection site, such as:
- Red, raised welts or hives
- Delayed localized swelling (“COVID arm”)
- Mild rash around the injection area
These reactions are mild, temporary, and resolve within a few days. Moderna’s vaccine shows slightly higher rates of injection site reactions, but the benefits of vaccination far outweigh these minimal risks.
PPE and Reducing Risk of Covid Rash
Proper PPE use in high-risk settings minimizes COVID-19 exposure. Masks, gloves, and face shields create barriers against viral transmission.
Extended PPE wear can cause skin irritation that mimics certain rashes. Proper PPE hygiene helps reduce both infection risk and skin complications.
Key practices include:
- Washing reusable masks regularly
- Changing disposable masks every 4-8 hours
- Applying barrier cream before extended PPE use
- Taking brief PPE breaks when safely possible
Healthcare workers and those in frequent public contact benefit most from consistent PPE protocols. Combined with vaccination, these measures provide layered protection.
Living With and Recovering From Covid-Related Skin Conditions
Recovery from COVID-related skin problems varies. Some conditions resolve quickly, while others persist for months.
Nearly 20% of patients develop dermatological symptoms after initial infection. Understanding these patterns helps guide care and set expectations.
Potential Complications and After-Effects
Post-COVID skin conditions can emerge weeks or months after infection. Up to 41% of affected individuals test positive for autoantibodies targeting the epidermis.
Common complications include:
- Chronic urticaria (persistent hives)
- Recurrent chilblain-like lesions on toes and fingers
- Pigmentation changes in about 6% of patients
- Pruritus (severe itching) in up to 25% of cases
- Subcutaneous nodules in roughly 12% of cases
Women and those with severe COVID-19 face higher risks of developing these complications. Dermatitis affects about 9.4% of post-COVID patients; edema and vesicular eruptions are less frequent.
Some patients experience viral reactivations, such as Epstein-Barr virus, triggering additional skin issues. Most lesions remain benign and eventually resolve, though treatment timelines vary.
Hair Loss and Other Lasting Skin Changes
Hair loss is one of the most distressing and common post-COVID skin changes. Studies report prevalence rates ranging from 1.5% to 52.7%, with most analyses showing that 23.9% to 32% of recovered patients experience noticeable hair thinning.
This condition, called telogen effluvium, typically appears two to four months after infection. Women, especially those hospitalized with severe COVID-19, often experience more pronounced hair loss than men.
Key characteristics of post-COVID hair loss:
- Usually temporary, but can persist beyond three months
- Affects hair density across the entire scalp
- Severity often correlates with initial infection intensity
- Recovery generally begins within six to nine months
Lasting changes in nail health and skin texture have also been documented. Some patients develop persistent rashes that cycle through improvement and flare-ups.